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Increased urinary excretion of C5b-9 distinguishes passive Heymann
nephritis in the rat. Increased urinary excretion of C5b-9 distinguishes
passive Heymann nephritis from other forms of experimental glomeru-
lonephritis in the rat. In the passive Heymann nephritis (PHN) model of
membranous nephropathy (MN) subepithelial deposits form from anti-
Fx1A antibody reacting with antigen expressed on the glomerular
epithelial cell membrane followed by membrane patching and shedding
of immune complexes. Immune complex deposits are accompanied by
deposits of C5b-9 which is required for the mediation of proteinuria. We
tested the hypothesis that C5b-9 assembly on the epithelial cell mem-
brane might result in C5b-9 excretion in the urine, which would
distinguish this autoimmune mechanism of MN from other processes
that result in subepithelial immune complex deposits. Using monoclo-
nal antibodies developed to rat C6 and a rat C5b-9 neoantigen, in a
sensitive ELISA assay, elevated urinary excretion of rat C5b-9 was
documented in PHN associated with on-going glomerular immune
deposit formation. No urinary C5b-9 was detectable in MN induced by
an exogenous antigen (cationized IgG) despite equivalent glomerular
C5b-9 deposits, or in models of nephrotoxic nephritis, subendothelial
immune complex nephritis, anti-mesangial cell membrane antibody-
induced nephritis or two non-immune nephropathies. Infusion of pre-
formed C5b-9 in proteinuric animals excluded glomerular filtration of
C5b-9 as a contributing mechanism to urinary C5b-9 excretion. We
conclude that in the rat, increased urinary excretion of C5b-9 is a
marker of MN induced by antibody to a glomerular epithelial cell
antigen. Urine C5b-9 excretion reflects active glomerular immune
deposit formation and distinguishes MN induced by this mechanism
from other forms of MN as well as from other glomerular diseases with
equivalent glomerular C5b-9 deposits.
The diagnosis of membranous nephropathy (MN), the most
common cause of idiopathic nephrotic syndrome in adults, can
be established only by renal biopsy [1]. The immune mecha-
nisms which mediate MN in man are unknown. Therapy is
therefore largely empiric and guided primarily by measure-
ments of the consequences of immune injury such as protein-
uria and renal function rather than by assessment of activity of
the underlying immunopathogenetic mechanism. Because of
the striking similarities between the clinical, histologic and
immunopathologic findings in idiopathic MN and those in the
Heyrnann models of MN in rats, most investigators strongly
suspect that the disease mechanisms in man are similar to those
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in the Heymann rat models (2, 31. Recent preliminary observa-
tions on antibody eluted from the kidney of a patient with MN
support this view [41.
In the passive Heymann nephritis model, recent studies have
established that glomerular immune deposit formation results
from binding of an antibody to an antigen expressed in coated
pits on the glomerular epithelial cell membrane followed by
patching and shedding of immune aggregates from the cell to
produce discontinuous subepithelial immune complex deposits
[5—81. Moreover, the alterations in glomerular permeability
which accompany this process appear to acquire assembly of
the complement C5b-9 (membrane attack) complex [reviewed
in 91, and C5b-9 deposits are prominent in both human and
experimental MN as well as other glomerular diseases [9—121.
With the above observations in mind, we reasoned that
epithelial cell membrane insertion of C5b-9 and subsequent
patching and capping phenomena might also result in increased
shedding of glomerular C5b-9 complexes into the urine. If
present, urinary C5b-9 might serve to distinguish the anti-cell
membrane antibody mechanism of MN from MN induced by
other mechanisms not involving cell membrane antigens, as
well as from other immune and non-immune glomerular dis-
eases.
Using a monoclonal antibody apparently reactive with a
neoantigen on rat C5b-9 in an ELISA assay, we found that
increased urinary C5b-9 excretion is present in MN induced by
antibody to rat glomerular epithelial cell antigen, and urinary
C5b-9 excretion accompanies on-going glomerular immune de-
posit formation. Increased urinary CSb-9 excretion was not
detectable in other forms of complement-dependent or -inde-
pendent experimental glomerular disease. These observations
may have significant implications for the diagnosis and therapy
of idiopathic MN in man.
Methods
Preparation of rat C5b-9 complexes and monoclonal
antibodies to rat C5b-9
Rat C5b-9 was prepared from rabbit erythrocytes lysed by
normal rat serum as described by Perkinson et al [121 using a
modification of the method of Biesecker et al [13]. Balb/c mice
were immunized by priming with 400g of the isolated C5b-9 in
complete Freund's adjuvant. Three further injections of 20 g,
20 g and 100 g rat C5b-9, respectively, were given during the
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next four weeks without adjuvant. Three days after the last
injection the spleen cells were prepared and fused with NS- 1
nonproducer myeloma cells using the fusion protocol of Fa-
zekas de St Groth and Scheidegg [14]. The fused cells were
cloned by limiting dilution. The supernatants were screened for
antibodies to rat C5b-9 by the presence of positive immunoflu-
orescence staining on cryostat sections from kidney biopsies of
rats with PHN, and negative staining on sections from rats with
PHN previously complement depleted with cobra venom fac-
tor. Positive IgG clones were recioned [15], propagated and
injected i.p. into pristane primed Balb/c mice. Monoclonal
antibodies (mabs) purified from ascitic fluid by ammonium
sulfate fractionation and DEAE-Sepharose (Pharmacia Fine
Chemicals, Piscataway, New Jersey, USA) chromatography
were biotinylated at I mg/mi in 100 m carbonate buffer (pH
7.7) using 50 g biotin-X-NHS (Caibiochem, La Jolla, Califor-
nia, USA) per mg of antibody [16].
Electrophoresis and immunoblotting
To identify the individual complement components detected
by the mabs, reactivity with rat EDTA-plasma and zymosan
activated serum (ZAS) separated by sodium dodecyl sulfate gel
electrophoresis (SDS—PAGE) was evaluated by immunobiot-
ting. SDS-PAGE was done as described by Hempelmann [17].
Three microliter of EDTA-plasma or ZAS mixed with 7 d of
sample buffer containing 0.5% SDS (wt/vol) and 50% glycerol
(vol/vol) (Baker, Phillipsburg, New Jersey, USA) were sepa-
rated by SDS-PAGE and then electrophoretically transferred to
nitrocellulose membranes (Schleicher and Schull, Keene, New
Hampshire, USA) using the method of Towbin, Staehlin and
Gordon [18]. Remaining protein binding sites were blocked with
PBS-gelatin for one hour. After washing with PBS either
biotin-labeled or unlabeled polyclonal or mabs were incubated
with the membranes. The rat complement components C6 and
C7 were identified using biotinylated monospecific goat IgG to
human C6 and C7 prepared from antisera obtained commer-
cially (Genzyme, Boston, Massachusetts, USA). Bound anti-
body was then detected after incubation of the membranes with
the appropriate second antibody (biotinylated sheep anti-mouse
IgG, Amersham, Arlington Heights, Illinois, USA) followed by
streptavidin-peroxidase (Amersham) and the peroxidase sub-
strate 4-chloro-l-naphtole (Merck, Sharp and Dohme, Rahway,
New Jersey, USA). Molecular weight calibration was done with
prestained standards obtained commercially (Bethesda Re-
search Laboratories, Gaithersburg, Maryland, USA).
Preparation of a zymosan activated rat serum (ZAS)
reference standard
Rat serum was incubated at 37°C with 20 mg/mI zymosan
(zymosan A, Sigma, St. Louis, Missouri, USA) for eight hours
with shaking and stored at —70°C. This serum was arbitrarily
assigned a value of 100 CSb-9 units/ml. Rat C5b-9 was found to
be stable upon repeated freezing and thawing of the ZAS.
Collection of rat plasma and urine samples for C5b-9
measurement
Three hundred microliters of blood were drawn from the tail
vein into syringes containing sufficient EDTA to result in a final
concentration of 60 m, and plasma was frozen at —20°C. In
order to avoid proteolytic degradation of urinary C5b-9 com-
plexes by naturally occurring proteases in the urine, urine was
collected in preservative yielding a final concentration of 10 mM
benzamidine (Sigma), 10 m epsilon-aminocaproic acid
(EACA,Sigma), 20 mri EDTA and 100 kallikrein inhibitor units!
ml of aprotinin (Sigma), 0.05% Tween 20 (Sigma) and 0.01%
NaN3 in Tris-HC1 buffer, pH 8.6. C5b-9 in urines was stable
under these conditions for over one month at 4°C.
ELISA for the detection of rat C5b-9 in plasma and urine
The mab 2A 1 directed against a rat CSb-9 neoantigen was
adjusted to 30 g/ml in 50 m carbonate buffer, pH 10.6. Three
sg (100 jsl) was coated to wells of microtitration plates (Dyna-
tech, Alexandria, Virginia, USA; Falcon, Becton-Dickinson,
Oxnard, California, USA) by incubation at 4°C for 16 hours.
Protein binding sites were blocked by incubating the wells with
PBS-gelatin for one hour at room temperature. One hundred l
of urine or plasma samples diluted in PBS-Tween containing the
same protease inhibitors as used for the collection of urine were
then placed in the wells at 4°C for 16 hours. The plates were
washed twice with PBS-Tween and 400 ng/well of the biotiny-
lated mab 3G 11 directed against rat C6 was added for two hours
at room temperature. The plates were washed three times with
PBS-Tween and a 1/1000 dilution of horseradish peroxidase
coupled to streptavidin (Amersham) were added. After an
incubation for one hour at room temperature, the wells were
washed four times with PBS-Tween and 100 sl of solution
containing 0.2 mri 2.2'-azino-di-(3-ethyl-benzthiazolinesulfo-
nate (ABTS, Boehringer Mannheim, Indianapolis, Indiana,
USA) and 2.5 mM H2O2 in 100 m acetate buffer at pH 5.0 was
placed in the wells. The color was allowed to develop for 30
minutes at room temperature. The extinction at 405 nm was
read using a Dynatech MR 560 microplate reader (Dynatech).
The amount of CSb-9 in every urine was calculated using a
linear calibration curve constructed with dilutions of standard
serum between 1/320 and the 1/5120. Urine samples were run in
four twofold serial dilutions starting with undiluted urine. Urine
concentrations of C5b-9 were calculated from OD values on the
linear part of the calibration curve (normally between OD 0.6
and 0.05) and corrected for the urine dilution.
The C5b-9 concentration in the lowest dilution of ZAS
standard which was significantly different from background
values using Student's t-test was taken as the detection limit of
the assay. The ability to recovery CSb-9 added to normal and
proteinuric urines was determined by addition of zymosan-
activated serum standard to undiluted urines containing prote-
ase inhibitors yielding a concentration of 5 C5b-9 units/mi. After
30 minutes to 24 hours at room temperature the samples were
diluted in the original Urines and C5b-9 was measured. The
amount of CSb-9 detected was divided by the amount added to
give percent recovery.
The minimum amount of C5b-9 that would have been detect-
able during a 24 hour period was determined in CSb-9 units/24
hrs using the following formula:
DL urine = DL ELISA x vol urine/% recovery x 100
where DL urine is detection limit (C5b-9 units/24 hrs), DL
ELISA the detection limit of the ELISA (0.01 C5b-9 units/mi),
vol urine is urine volume (m1124 hrs), and % recovery is
percentage of C5b-9 recovered after addition of CSb-9 to urine.
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Inhibition of the rat C5b-9 assay with polyclonal antisera to
human terminal complement components
In order to identify the complement component on which the
antigenic epitope detected by the 2A1 mab to a C5b-9 neoanti-
gen is localized, a 1/160 dilution of the zymosan activated serum
standard (0.625 C5b-9 units/mi) was preincubated with twofold
serial dilutions of goat antisera to human C9, C7 (Genzyme) and
normal goat serum starting at a 1/20 dilution. After one hour at
room temperature the samples were added to ELISA plates
coated with the 2A1 mab and the C5b-9 concentration was
measured as described above. Results are expressed as C5b-9
detected/C5b-9 added x 100.
Induction of experimental glomerulonephritis
General. All models of experimental glomerulonephritis were
induced in male Sprague Dawley rats (Tyler Laboratories,
Bellevue, Washington, USA). Urines were collected in meta-
bolic cages with free access to water. Urine protein excretion
was measured using a sulfosalicylic acid method and a whole
serum standard (Lab Trol, Dade Diagnostics, Aquado, Puerto
Rico, USA) [19]. Renal biopsies were obtained under ether
anesthesia and processed for immunofluorescence microscopy
as described below.
a. Passive Heymann nephritis (PHN). PHN was induced in
eight rats by i.v. injection of sheep antibody to Fx 1A prepared
as described in detail elsewhere [20, 21]. Selected animals
underwent renal biopsy, and urine and serum collections to
provide data on days zero, one, two, three, four and seven. In
most animals, urines were collected from days four to five. In
another group of animals, renal biopsies were obtained daily
from day one to five and stained for sheep IgG, rat C3 and rat
C5b-9. The effect of complement depletion on glomerular C5b-9
deposition and urinary C5b-9 excretion was studied in two PHN
rats depleted of complement by administration of cobra venom
factor (Cordis Laboratories, Miami, Florida, USA) prior to
anti-Fx lA injection, and daily thereafter using a protocol
described previously [22].
b. Cationic IgG induced membranous nephropathy. To study
a model of membranous nephropathy induced by a planted
exogenous antigen, human IgG (Miles Scientific, Naperville,
Illinois, USA) was cationized as described by Oite et al [23]
using a modification of carbodiimide method of Danon et al [24].
Isoelectric points of cationized IgG bands ranged from 8.1 to 9.3
by isoelectric focusing. After removal of the left kidney, the
cationized antigen (125 p.g in 500 pA PBS) was perfused ex vivo
via the superior mesenteric artery into the right kidney of five
experimental rats using a perfusion protocol described in detail
elsewhere [25]. Thirty minutes after perfusion, 0.9 ml of heat-
inactivated (56°C, 30 mm) rabbit anti-human IgG antiserum or
normal rabbit serum was given i.v. Urine protein excretion was
measured from 0 to 24 hours, and renal biopsies were obtained
24 hours after antibody injection.
c. Nephrotoxic nephritis. Nephrotoxic (anti-GBM) nephritis
was induced in six rats by a single injection of sheep anti-rat
GBM antibody, the characteristics of which have been pub-
lished elsewhere [26]. Urines were collected from 0 to 24 hours,
and renal biopsies obtained 24 hours after antibody injection.
d. Subendothelial immune complex nephritis. Nephritis due
to subendothelial formation of immune complex deposits was
produced as described in detail elsewhere [27]. Briefly, the right
kidney was perfused as described above with 180 jg of conca-
navalin A (Miles Scientific) in 0.4 ml PBS followed by 20 mg of
rabbit anti-con A IgG [28]. The urine was collected during the
subsequent 24 hour period, and renal biopsies were obtained 24
hours following antibody injection.
e. Anti-mesangial cell antibody glomerulonephritis. To eval-
uate another form of glomerulonephntis induced by antibody to
a resident, non-epithelial glomerular cell antigen, the anti-Thy 1
antibody-induced model of glomerulonephritis was produced in
three rats [291. Thymocytes were prepared from 10-month-old
Lewis rats, and i08 cells were used to immunize rabbits three
times in complete Freund's adjuvant. Six weeks after the initial
immunization, immune IgG was isolated by ion exchange
chromatography, On cryostat sections of normal kidney, the
antibody reacted primarily with mesangial areas by indirect
immunofluorescence. It stained glomerular mesangial cells in
culture and failed to stain glomerular epithelial cells in culture
[30]. Mesangial glomerulonephritis was induced by injection of
10, 15 or 20 mg of anti-Thy 1 antibody i.v. Urine was collected
from 0 to 24 hours and renal biopsies were obtained 24 hours
after antibody injection.
f. Aminonucleoside nephrosis (PAN). PAN was induced in
six rats by a single intravenous injection of 0.1 mg/kg of PAN
(ICN Pharmaceuticals, Inc., Cleveland, Ohio, USA) [31]. Urine
protein excretion was measured from days 3 to 4, 10 to 11 and
16 to 17. To study the possible glomerular filtration of circulat-
ing C5b-9 complexes as a contributing factor to urinary C5b-9
excretion, five proteinuric PAN rats (113 38 mg/day) were
injected with 100 units of C5b-9 as ZAS, and measurements of
plasma C5b-9 were carried out before, one minute and 24 hours
after injection. Urinary C5b-9 measurements were made in the
urine collected for the 24 hours after C5b-9 injection.
g. Remnant kidney. A remnant kidney model was induced in
five rats by left nephrectomy and subsequent ligation of several
branches of the right renal artery until 2/3 to 5/6 of the right
kidney was unperfused. Following renal ablation, urines were
collected from day seven to eight and 10 to 11.
Renal pathology
Fresh renal tissue obtained at open renal biopsy was proc-
essed for immunofluorescence microscopy as described previ-
ously [32]. Immunofluorescence to detect C5b-9 with biotiny-
lated mab 2A 1 was done by adding 600 ng of antibody in a
volume of 20 pA to tissue sections which had been prepared as
described above. After an incubation at room temperature for
one hour, the slides were washed three times with PBS and 20
p.l of a 1:200 dilution of fluorescein-labeled streptavidin (Amer-
sham Corporation) were added and incubated for 30 minutes at
room temperature. Rat C3 and sheep IgG were detected using
fluorescein labeled antibodies (goat anti-rat C3, rabbit anti-
sheep IgG, Organon Teknika-Cappel, Westchester, Pennsylva-
nia, USA). The intensity of immunofluorescence was graded
semiquantitatively as follows: trace, barely detectable; 1+,
present but faint; 2+, average staining intensity; 3+, strong
standing intensity; 4+, maximal staining intensity.
molecular
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Fig. 1. Characterization of monoclonal antibodies to the rat C5b-9
complex. Rat EDTA-plasma (lanes A, B, E, G, H) and zymosan-
activated rat serum standard (lanes C, D, F) were separated on
SDS-PAGE. After transfer to nitrocellulose membranes the lanes were
reacted with the following antibodies: A, polyclonal goat anti-human
C6; B, C: monoclonal antibody 3G1 1; D, E: monoclonal antibody 2A1;
F, G: monoclonal antibody 2H8; H: polyclonal goat anti-human C7.
3G1 I identifies the same protein in EDTA-plasma as antibody to human
C6 (lanes A, B) whereas 2H8 identifies rat C7 which is also detected by
goat anti-human C7 (lanes G, H). Reacted against ZAS, both monoclo-
nal antibody 3G1 1 and 2H8 also identify a second high molecular weight
band (lanes C, F) which presumably represents the C5b-9 complex of
rat complement. Monoclonal antibody 2Al reacts intensely with this
high molecular weight complex in ZAS but fails to sustain any native
complement components in EDTA plasma (lane E), suggesting reactiv-
ity with a neoantigen of the C5b-9 complex.
Results
Specificity of the monoclonal antibodies for rat C5b-9 and
establishment of the rat C5b-9 ELISA
Three monoclonal antibodies (2H8, 2A1, 3011) obtained after
screening of the hybridoma cultures were further characterized
using SDS-PAGE and immunoblotting. The mab 3G11 identi-
fied the same protein in EDTA-plasma as did the antibody to
human C6 (Fig. 1, lanes A, B) whereas the mab 2118 identified
C7 as seen by comparison with a polyclonal antibody to human
C7 (Fig. I, lanes 0, H). When tested against ZAS both the
anti-rat C6 (mab 3G1 1) and anti-rat C7 (mab 2H8) antibodies
also identified a second high molecular weight band (Fig. 1,
lanes C, F) which presumably represents the C5b-9 complex of
rat complement. The mab 2A1 intensely reacted with this high
molecular weight component in ZAS but failed to stain EDTA-
plasma (Fig. 1, lane D, E), suggesting reactivity with a neoan-
tigen of the C5b-9 complex which is not present on any of the
precursor components.
Inhibition of the C5b-9 ELISA by anti-human C9
In order to identify the complement component detected by
the 2A1 mab rat zymosan activated serum was preincubated
with polyclonal goat antibodies to human C7, C9 and normal
goat serum. As indicated in Figure 2, only preincubation with
anti-human C9 inhibited the assay in a dose dependent manner.
The mab 2A1 mab therefore seems to compete with antibodies
to human C9 for its binding site on the C5b-9 complex,
indicating that the reactive epitope is located on the C9 mole-
cule.
1/320 1/1280
Dilution of antiserum
Fig. 2. Inhibition of the rat C5b-9 ELISA by antisera to human
complement components. Rat ZAS was preincubated with polyclonal
goat antiserum to human C9 (circles), goat antiserum to human C7
(squares) and normal goat serum (triangles). Antiserum to human C9
inhibited the detection of rat C5b-9 complexes indicating that the
epitope detected by the mab 2Al is located on rat C9.
Characteristics of the C5b-9 ELISA
A calibration curve obtained by assaying twofold serial
dilutions of zymosan-activated rat serum is depicted in Figure 3
with EDTA-plasma as negative control. The detection limit was
0.01 C5b-9 units/ml. The assay also detected detergent solubi-
lized C5b-9 complexes obtained from rat complement lysed
erythrocytes (data not shown).
Detection of rat C5b-9 in urine and plasma
When zymosan activated serum was added to normal rat
urine (N = 4), 104.9 15.0% (mean SD) of the added C5b-9
was recovered when the assay was performed immediately and
93.2 8.0% was recovered when the assay was performed after
24 hour incubation at room temperature. Less C5b-9 was
recovered when C5b-9 was added to proteinuric urines which
did not initially contain measurable CSb-9. Recovery rates of
added C5b-9 in these urines were used to calculate the 24-hour
detection limits indicated in Table 2.
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Plasma or serum dilution
Fig. 3. Calibration curve of the rat C5b-9
ELJSA. Four separate samples of rat EDTA-
plasma (t) or ZAS (•) were run in twofold
serial dilutions. Values obtained at 1: 10,000
dilution of ZAS were significantly different
from background values (P < 0.01).
Table 1. Glomerular deposition and urinary cxcretion of rat C5b-9 in passive Heymann nephritis
Days after anti-FxIA antibody injection
0 1 2 3 4 5
Glomerular immunofluorescence
Sheep IgG (N = 4)
Rat C3 (N = 4)
Rat C5b-9 (N = 4)
ND
ND
ND
2-3+
1+
0—T+
2-4+ 2-4+
2-3+ 2-3+
1—2+ 1—3+
2-4+
3-4+
2—3+
2-4+
3—4+
2—3+
Urine C5b-9 excretion
units/24 hr
Plasma C5b-9 units/mi
Urine protein mg/24 hr
0
1.2 Q•3b
4.2 2l
0.03 0,04b
5.0 1.6
4.5 1.3
0.6 0.3 3.0 2.0
2.8 0.4 2.2 0.6
3.2 0.3 9.8 6.0
2.2 1.0
1.9 0.5
20.7 15.2
3.6 3.3
1.1 0,2
57.4 44.6
a Not doneb Mean SD
Excretion of C5b-9 in urines from rats with passive Hey,nann
nephritis (PHN)
Proteinuria greater than 10 mg/24 hr was induced in PHN rats
on days 3 to 4 after the injection of anti-FxLA (Table 1).
However, all rats had detectable levels of urine C5b-9 excretion
averaging 0.6 0.5 units/24 hr on the second day after injection
of anti-Fx1A. This level increased to 3.0 2.0 units/24 hr on the
third day (P < 0.001 vs. day two) and was 3.6 3.5 units/24 hr
on the fifth day (P < 0.01 vs. day two; Table 1). No excretion
of C5b-9 was detectable in PHN rats depleted of complement by
treatment with cobra venom factor. With the onset of the
autologous phase and glomerular deposition of rat anti-sheep
IgG, urinary C5b-9 excretion increased to 8.7 6.6 Units on
days 7 to 8.
Glomerular immunofluorescence
Glomerular deposits of sheep IgG were present on the first
day after injection of anti-FxJA (Table 1). One, 2 + glomerular
deposition of CSb-9 became detectable on the second day
(Table 1). C5b-9 increased to 3 + on the third day and thereafter
(Table 1, Fig. 4A). Glomerular staining for C3 paralleled stain-
ing for C5b-9. Rat IgG was not detected in glomeruli until day
five. Careful studies failed to detect sheep IgG, rat C3 or rat
C5b-9 on the brush border of proximal tubular cells at any point
during the study (Fig. 4C). Treatment of two PHN rats with
CVF abolished glomerular C5b-9 and C3 deposition as well as
urinary C5b-9 excretion (Fig. 4B).
Plasma levels and glomerular filtration of C5b-9
Plasma levels of CSb-9 were 5.0 units/mi on the first day and
decreased to levels seen before the injection of anti-Fx1A over
the next four days (Table 1). Urinary C5b-9 excretion did not
parallel plasma levels of C5b-9. Because PHN rats were not
proteinuric when C5b-9 levels in plasma were highest, we
addressed the question whether elevated plasma levels of CSb-9
could contribute to urinary C5b-9 excretion in proteinuric rats
by inducing elevated serum C5b-9 levels in rats already made
proteinuric by prior administration of PAN. Five rats with
aminonucleoside nephrosis that had heavy proteinuria but no
detectable C5b-9 in the urine 17 days after administration of
PAN, were injected i.v. with ZAS containing 100 units of
C5b-9. C5b-9 plasma levels at one minute were increased to
14.1 units/mI, or about three times the maximal levels seen early
in PHN (Table 1) and normal values by the end of 24 hours.
However, C5b-9 was not detected in the urine of injected rats
despite a urinary protein excretion of 153 27 mg124 hr.
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Table 2. Urinary C5b-9 excretion in experimental glomerular disease
Glomerular C5b-9
Urinary excretion
Protein C5b-9
N Day deposits mg/24 h u/24 hr
Passive Heymann 8 5 + subepithelial 53 l6 3.6 1.2k
nephritis
Cationized IgG 5 2 + subepithelial 165 40 <0.71 0.19"
anti-IgG
Nephrotoxic 6 1 linear GBM 423 60 <0.43 0.14"
nephritis
Con-A anti-con-A 4 2 + subendothelial 88 12 <0.82 0.24"
Anti-thy 1 3 2 + mesangial 4 I <0.15 0.02"
Aminonucleoside 6 17 — 170 38 <0.24 0.03"
nephrosis
Remnant kidney 5 10 — 8 1 <0.17 0.03"
a Mean SEM.
b CSb-9 excretion was not detected in this group. The value reported represents and indicates the mean SEM of the maximal amount of C5b-9
that could have been excreted in 24 hrs without being detected by the assay in this group (Methods).
Urinary C5b-9 excretion in other forms of experimental A-anti-con A) and mesangial deposits (anti-Thy 1) also had no
glomerulonephritis detectable urinary CSb-9 despite readily-detectable glomerular
C5b-9 deposits (Table 2, Figs. 4E and 4F). Models of immune
Excretion of C5b-9 was not detectable in membranous and non-immune glomerular injury which were not associated
nephropathy induced by an exogenous antigen (cationized IgG) with glomerular C5b-9 deposits, including nephrotoxic nephri-
despite levels of proteinuria and glomerular C5b-9 deposits tis, aminonucleoside necrosis and the remnant kidney model,
which exceeded those seen in PHN (Table 2, Fig. 4D). More- also failed to exhibit detectable C5b-9 excretion in urine (Table
over, nephritis associated with subendothelial deposits (con 2).
Fig. 4. Iu,,,,unofluorccent staining for glomerular deposits of CSb-9 in several
models of experimental glo,nerulonephritLc studied. A. Passive Heymann
nephritis at five days: B. Passive Heymann nephritis treated with cobra venom
factor at five days: C. Proximal tubules in proteinuric rats with passive
Heymann nephritis at five days: D. Cationized lgG-anti-lgG model of
membranous nephropathy on day one; E: Con A-anti-con A model of
subendothelial immune complex glomerulonephritis on day two: F.
Glomerulonephritis induced with anti-thy I on day one: C. Normal rat kidney
(original magnifications 25O).
'
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Discussion
C5b-9 membrane attack complexes are assembled from five
precursor molecules present in the serum in inactive form.
Proteolytic cleavage of C5 by the C5 convertase of either the
classical or alternative complement pathway generates C5b
which initiates assembly of the C5b-9 complex [33]. The last
step of C5b-9 complex formation involves polymerization of C9
which accompanies insertion of the complex into the lipid
bilayer of cell membranes [34]. When complement is activated
in serum in the absence of cell membranes, C9 polymerization
is inhibited by the action of S protein resulting in water soluble
complexes [33]. During formation of C5b-8 and C9 polymeriza-
tion, neoantigens are expressed which are unique to the C5b-9
complex and are not expressed on any of the individual native
complement components. Antibodies to such neoantigens have
been utilized to demonstrate C5b-9 deposition in a variety of
human and experimental glomerular diseases [10—12]. Our
monoclonal antibody 2Al exhibited the characteristics of anti-
body to a C5b-9 neoantigen by SDS-PAGE and immunoblotting
studies and was utilized as the capturing antibody in our ELISA
assay. The bound C5b-9 was then detected using a second
monoclonal antibody reactive with rat C6. This double antibody
ELISA assay, similar in principle to assays used by others to
measure C5b-9 in serum [35], exhibited excellent sensitivity and
specificity for detecting rat C5b-9 in serum and urine.
Our data document an easily detectable increase in urinary
excretion of the C5b-9 complex concomitant with the onset of
glomerular immune deposit formation in the passive Heymann
nephritis (PHN) model of MN in rats. Elevated urinary C5b-9
excretion preceded the onset of detectable increases in total
urinary protein excretion. It parallels the course of glomerular
immune deposit formation as defined by immunofluorescence
studies and previous quantitative measurements of glomerular
antibody deposition which document on-going deposit forma-
tion for several days following a single antibody injection [21].
Urinary excretion of C5b-9 was present in detectable quantities
only in MN induced by an antibody to a glomerular epithelial
cell membrane antigen and was absent or below detection limits
with subepithelial immune complex formation induced by an
exogenous antigen, immune complex formation at other sites,
or deposition of antibody against mesangial cell membranes
despite extensive glomerular C5b-9 deposits in most of these
lesions. The levels of urinary C5b-9 excreted in PHN exceeded
the sensitivity levels of the assay in these models by 4- to
20-fold.
While there is no obvious way to definitively establish that
the urinary C5b-9 complexes measured were derived from
glomeruli, there are several reasons to believe that they were
not of pre- or post-glomerular origin. Thus, although a transient
increase in circulating serum C5b-9 complexes was observed on
days 1 to 2 following injection of anti-FxlA antibody to induce
PHN, urinary complexes were barely detectable at this point
and rose to peak levels only on days 3 to 4 when serum C5b-9
levels had returned to levels seen before the injection of
antibody. When soluble C5b-9 complexes, which have a molec-
ular weight of about 1000 kd [33], were exogenously adminis-
tered to rats with a marked and non-selective increase in
glomerular permeability induced by prior injection of aminonu-
cleoside of puromycin, serum levels of C5b-9 that exceeded
peak levels in PHN by threefold were produced. However, no
detectable urinary C5b-9 excretion occurred. Thus filtration of
the intact C5b-9 complex, even by abnormally permeable
glomeruli, appears to be minimal and insufficient to account for
our findings.
A post-glomerular origin of the urinary complexes could be
postulated based on the extensive reactivity of the anti-Fx1A
antibody used to induce PHN with antigens expressed on
proximal tubular brush border as well as glomerular antigens
[20, 21], and the known presence of the putative antigen in this
model, GP330, on both glomerular and tubular epithelial cells
[6]. However, increased urinary C5b-9 excretion preceded any
detectable increase in urine protein excretion in PHN, and
careful immunofluorescence studies failed to demonstrate tubu-
lar brush border deposition of C5b-9 at any point in the course
of disease development. Previous studies have noted faintly
positive staining for IgG on proximal tubular brush borders at
the time of peak circulating antibody levels early on day one,
which usually diminish thereafter [211. C5b-9 excretion fol-
lowed the opposite course. However, other studies in models of
active Heymann nephritis 1361 which may be mediated by a
similar mechanism [37], and studies of anti-brush border anti-
bodies passively transferred to rats with proteinuria secondary
to chronic serum sickness, have noted that IgG, C3 and C5b-9
were components of tubular brush border deposits [7, 38, 39],
although tubular injury is apparently complement independent.
Although we cannot exclude other sources with certainty, we
believe our data, and the studies of others, strongly support the
conclusion that the urinary C5b-9 complexes measured did
result from glomerular immune deposit formation.
Our data do not define the mechanism by which glomerular
C5b-9 complexes reach the urinary space. Our studies in
aminonucleoside nephrosis make it improbable that they do so
by crossing any component of the glomerular filtration barrier.
Other possibilities exist. Filtration of antibody IgG may result
in initial deposit formation in coated pits containing GP330 on
the urinary space surface of the glomerular podocyte [6]. C5b-9
might be transported into the urine directly or by rearrangement
of the cell membrane during the patching and capping process
induced by binding of antibody, as observed in cultured gb-
merular epithelial cells [8]. Finally, cellular endocytosis of the
immune aggregates containing C5b-9, or of the CSb-9 complex
alone, with transcellular transport and subsequent exocytosis
into the urinary space may be possible. Preliminary immuno-
cytochemical localization studies of the C5b-9 complex and
sequential studies of its movement suggest that the latter
mechanism probably accounts for our findings in PHN [40].
This phenomenon of endocytosis and exocytosis of the CSb-9
complexes by nucleated cells would accord with recent dem-
onstration of a similar phenomenon in neutrophils [41], as well
as with the observation that C5b-9 on the glomerular epithelial
cell in vitro appears to be inserted into the cell membrane and
handled by the cell differently from the antigen antibody com-
plexes which are shed from the cell surface [421.
A somewhat surprising finding in our study was that detect-
able levels of urinary C5b-9 excretion were seen only in PHN
and were not found in other forms of MN or other glomerular
immune complex diseases despite extensive glomerular C5b-9
deposition in other models. MN induced by in situ immune
complex formation with a cationized exogenous IgG antigen
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shares with PHN the characteristics of subepithelial immune
complex deposits, glomerular C5b-9 deposition, and heavy
proteinuria probably due to a C5b-9 dependent mechanism of
injury [43, 44]. However, urinary C5b-9 excretion was below
detection limits in this model despite glomerular immune de-
posits and proteinuria which equalled or exceeded those in
PHN. Our data therefore suggest that only immune deposits
formed on the glomerular epithelial cell membrane itself, pre-
sumably accompanied by cell membrane insertion of C5b-9,
result in urinary C5b-9 excretion whereas immune complex
deposits formed in a subepithelial distribution by planted exog-
enous antigens localized on a charge basis and apparently not
involving membrane C5b-9 insertion do not cause detectable
urinary C5b-9 levels. Similar negative results were found with
nephritis induced by subendothelial immune complex deposits
of concanavalin A and anti-concanavalin A, a neutrophil-
mediated model of glomerulonephritis which also has promi-
nent C5b-9 deposits [27, 28]. Induction of glomerulonephritis
due to formation of immune deposits on the mesangial cell
membrane resulted in glomerular C5b-9 deposition but no
urinary C5b-9 excretion, presumably reflecting interposition of
mesangial matrix between these cells and the urinary space.
Yamamoto and Wilson have recently characterized this model
and suggested that immune injury may be C5b-9 mediated [29].
The lack of urinary C5b-9 excretion in complement-indepen-
dent anti-GBM nephritis and in the non-immune lesions of
aminonucleoside necrosis and renal ablation nephropathy fur-
ther support the specificity of elevated urinary C5b-9 excretion
for lesions induced by antibody to the glomerular epithelial cell
membrane.
While the availability of multiple models of glomerular dis-
ease in the rat which exhibit immunopathologic features of
immune mediated renal disease in man allows easy definition of
the specificity of elevated urinary C5b-9 levels for various types
and mechanisms of glomerular disease, the utility of a similar
assay in man will obviously require independent confirmation
using an assay for human C5b-9 that is functional in human
urine. The pathogenesis of MN in man remains unknown. If
idiopathic MN is an autoimmune disease involving antibody to
glomerular epithelial cell membranes, as preliminary data sug-
gest [4], the nephritogenic antibody does not appear to be
directed against an antigen shared with proximal tubular brush
border as it is in the Heymann rat model [45, 46]. Nevertheless,
our findings suggest that measurement of urinary C5b-9 com-
plex excretion might provide a useful non-invasive diagnostic
test for such an entity. Moreover, the availability of a readily
measured parameter which provides an index of the activity of
the disease mechanism against which therapy is directed could
be of major clinical significance. The findings in the present
study provide substantial impetus for the pursuit of such a goal.
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